Trial
NCT04057365
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Massachusetts General Hospital
Collaborators
Bristol-Myers Squibb; Leap Therapeutics, Inc.
Condition
Biliary Tract Cancer
Intervention
Nivolumab
Why stopped
Based on a Simon 2-stage design, this study did not meet response criteria to proceed to stage 2.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-13